News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZS Pharma Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Evaluating ZS-9 for the Treatment of Hyperkalemia


10/23/2013 10:16:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, announced that it has completed enrollment in its Phase 3 pivotal trial (ZS-003) evaluating the ability of ZS-9 to treat hyperkalemia. Hyperkalemia is a life-threatening condition that is characterized by higher than normal levels of potassium (K+) in the blood serum. Underlying causes of hyperkalemia include chronic kidney disease, heart failure, diabetes, and cardio-renal protective RAAS inhibitor therapies, such as ACEs, ARBs and aldosterone blockers.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
ZS Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES